Early Detection of Ovarian and Endometrial Cancer Using Genomic Testing from Uterine Pap and Saliva Samples

What this Trial Is About

Researchers are studying a new test to detect ovarian and endometrial cancers early by identifying specific genetic mutations. These cancers are among the most common and deadly for women in high-income countries, mainly due to late-stage diagnosis. The study focuses on peri- and post-menopausal women and aims to improve early detection by analyzing mutations in samples from a uterine pap test and saliva, alongside advanced machine learning techniques. The test uses a panel of genes linked to ovarian and endometrial cancers and includes low-pass whole genome sequencing combined with a machine-learning classifier to distinguish cancer from benign gynecologic conditions. Participants are divided into two groups those with suspected or confirmed upper genital tract cancer scheduled for tumor removal surgery, and those undergoing hysterectomy or related surgery for presumed benign conditions. The study collects samples and evaluates mutations over three years. Participants will provide uterine pap test and saliva samples for genetic analysis. Researchers will assess the presence of cancer-related mutations, patient experiences including pain and acceptability, and any risks associated with the test during the three-year period. The study is observational, gathering data and samples without altering treatment, with the goal of validating this genomic approach for early cancer diagnosis.

DOvEEgene/WISE Genomics: Diagnosing Ovarian and Endometrial Cancer Early Using Genomics